SAB Biotherapeutics (SABS) Operating Income (2021 - 2026)
SAB Biotherapeutics (SABS) posted Operating Income of -$20.0 million for Q1 2026, down 26.81% on a QoQ basis from -$15.8 million in Q4 2025, and down 85.64% year-over-year from -$139.3 million in Q1 2025.
SAB Biotherapeutics (SABS) Operating Income (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Operating Income history runs 6 years deep, the most recent figure standing at -$20.0 million for Q1 2026.
- Quarterly Operating Income fell 85.64% year-over-year to -$20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.2 million (down 37.56% YoY) and the FY2025 annual result came in at -$49.0 million, down 14.08% from the prior year.
- Operating Income was -$20.0 million for Q1 2026 at SAB Biotherapeutics, down from -$15.8 million in the prior quarter.
- Across five years, Operating Income topped out at -$5.3 million in Q3 2023 and bottomed at -$20.0 million in Q1 2026.
- A 5-year average of -$10.5 million and a median of -$10.0 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income slumped 924.07% — and 2024, when it soared 46.97%.
- SAB Biotherapeutics' Operating Income stood at -$7.9 million in 2022, then tumbled by 140.12% to -$18.9 million in 2023, then surged by 46.97% to -$10.0 million in 2024, then sank by 57.56% to -$15.8 million in 2025, then declined by 26.81% to -$20.0 million in 2026.
- Business Quant data shows SABS's Operating Income at -$20.0 million in Q1 2026, -$15.8 million in Q4 2025, and -$12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | -20.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.00 Mn |
| Dec 31, 2025 | -15.77 Mn |
| Sep 30, 2025 | -12.68 Mn |
| Jun 30, 2025 | -9.73 Mn |
| Mar 31, 2025 | -10.77 Mn |
| Dec 31, 2024 | -10.01 Mn |
| Sep 30, 2024 | -11.31 Mn |
| Jun 30, 2024 | -10.20 Mn |
| Mar 31, 2024 | -11.39 Mn |
| Dec 31, 2023 | -18.87 Mn |
| Sep 30, 2023 | -5.32 Mn |
| Jun 30, 2023 | -6.48 Mn |
| Mar 31, 2023 | -7.40 Mn |
| Dec 31, 2022 | -7.86 Mn |
| Sep 30, 2022 | -7.81 Mn |
| Jun 30, 2022 | -6.54 Mn |
| Mar 31, 2022 | -6.71 Mn |
| Dec 31, 2021 | -7.34 Mn |
| Sep 30, 2021 | -3.99 Mn |
| Jun 30, 2021 | -2.87 Mn |